Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.54 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.54 |
| ▸ | FSHR | P23945 | 4/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634038 | 0.90 | DRD2 (0.59) | DRD2DRD3ADRA1AFSHRNPC1 | |
| SCHEMBL14633906 | 0.89 | DRD2 (0.61) | DRD2DRD3ADRA1AFSHRNPC1 | |
| SCHEMBL14634146 | 0.89 | DRD2 (0.52) | DRD2DRD3ADRA1AFSHRHDAC3 | |
| SCHEMBL14634064 | 0.87 | DRD2 (0.56) | DRD2DRD3ADRA1AFSHRNPC1 | |
| SCHEMBL14634003 | 0.86 | DRD2 (0.59) | DRD2DRD3ADRA1AFSHRNPC1 | |
| SCHEMBL19291178 | 0.86 | DRD2 (0.59) | DRD2DRD3ADRA1AFSHRNPC1 | |
| SCHEMBL14633951 | 0.85 | DRD2 (0.61) | DRD2DRD3ADRA1AFSHRNPC1 | |
| SCHEMBL14633515 | 0.83 | DRD2 (0.56) | DRD2DRD3ADRA1AFSHRNPC1 | |
| SCHEMBL14633895 | 0.83 | DRD2 (0.54) | DRD2DRD3ADRA1AFSHRNPC1 | |
| SCHEMBL14633914 | 0.83 | DRD2 (0.55) | DRD2DRD3ADRA1AFSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938262-B2 | Benzamides | MERCK PATENT GMBH (DE) | 2018-04-10 | — | — | US | disclosed |
| EP-3263568-A1 | BENZAMIDES | Merck Patent GmbH (DE) | 2018-01-03 | — | — | EP | disclosed |
| EP-2734517-B1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| US-20170022191-A1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2017-01-26 | — | — | US | disclosed |
| US-9498475-B2 | Benzamides | MERCK PATENT GMBH (DE) | 2016-11-22 | — | — | US | disclosed |
| US-20160022670-A1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| US-9181226-B2 | Benzamides | MERCK PATENT GMBH (DE) | 2015-11-10 | — | — | US | disclosed |
| US-20130023522-A1 | BENZAMIDES | MERCK PATENT GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022670-A1 | BENZAMIDES | FSHR, GNRHR, LHCGR | DRD2 1495/4885DRD3 1984/4885ADRA1A 169/4885 |
| US-20170022191-A1 | BENZAMIDES | FSHR, GNRHR, LHCGR | DRD2 1495/4885DRD3 1984/4885ADRA1A 169/4885 |
| US-20130023522-A1 | BENZAMIDES | FSHR, GNRHR, LHCGR | DRD2 1309/4885DRD3 1697/4885ADRA1A 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.